Clinical Trial Update: SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the SOX regimen (S-1 plus oxaliplatin) as neoadjuvant chemotherapy for AJCC stage II-III gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Lin Chen | Conditions: Gastric Adenocarcinoma | Phase 3 | Status: UNKNOWN